New drug aimed at stopping silent attack on transplanted kidneys
NCT ID NCT02113891
Summary
This study aimed to see if a drug called eculizumab could treat a hidden form of rejection in kidney transplant patients. The goal was to stop this early, silent damage from turning into permanent kidney scarring. The trial planned to give the drug to a small group of patients and compare their results to past patients who did not receive it, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.